HemaQuest Pharmaceuticals Receives European Orphan Medicinal Product Designations for Therapeutic to Treat Hemoglobin Disorders BOSTON, MA--(Marketwire - March 26, 2009) - HemaQuest Pharmaceuticals today announced that it has received two orphan medicinal product designations from the European Commission for its product...

HemaQuest Pharmaceuticals Announces Clinical Progress on New Sickle Cell Anemia Drug SAN FRANCISCO, CA--(Marketwire - December 9, 2008) - HemaQuest Pharmaceuticals announced today the successful completion of Phase 1 clinical trials of HQK-1001, an orally-administered therapeutic...